Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;22(10):1306-12.
doi: 10.1002/pro.2317. Epub 2013 Aug 19.

Inactivating mutation in histone deacetylase 3 stabilizes its active conformation

Affiliations

Inactivating mutation in histone deacetylase 3 stabilizes its active conformation

Mehrnoosh Arrar et al. Protein Sci. 2013 Oct.

Abstract

Histone deacetylases (HDACs), together with histone acetyltransferases (HATs), regulate gene expression by modulating the acetylation level of chromatin. HDAC3 is implicated in many important cellular processes, particularly in cancer cell proliferation and metastasis, making inhibition of HDAC3 a promising epigenetic treatment for certain cancers. HDAC3 is activated upon complex formation with both inositol tetraphosphate (IP4) and the deacetylase-activating domain (DAD) of multi-protein nuclear receptor corepressor complexes. In previous studies, we have shown that binding of DAD and IP4 to HDAC3 significantly restricts its conformational space towards its stable ternary complex conformation, and suggest this to be the active conformation. Here, we report a single mutation of HDAC3 that is capable of mimicking the stabilizing effects of DAD and IP4, without the presence of either. This mutation, however, results in a total loss of deacetylase activity, prompting a closer evaluation of our understanding of the activation of HDAC3.

Keywords: HDAC3; R265P; allostery; conformational selection; molecular recognition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cartoon representation of HDAC3 (green ribbon) bound to DAD (purple ribbon) and IP4 (sticks), from Protein Data Bank (PDB) identification code: 4A69. Arrow indicates the location of the active site. For reference, some loops and helices are identified, as well as the location of the R265 residue.
Figure 2
Figure 2
Principal component analysis of HDAC3. (A) apo HDAC3, (B) IP4-bound HDAC3, (C) DAD-bound HDAC3, (D) IP4- and DAD-bound HDAC3, and (E) apo HDAC3R265P mutant dynamics are each projected onto PC1:PC2 space of the apo HDAC3WT. A white cross in each panel indicates the projection of the HDAC3:IP4:DAD crystal structure (PDB ID: 4A6910).
Figure 3
Figure 3
formula image Analysis of mutant and complexed HDAC3. Differences between per-residue RMSF values (Å) are shown for (from top to bottom) HDAC3:IP4:DAD, HDAC3:DAD, HDAC3:IP4, and HDAC3R265P, with reference to the apo HDAC3WT RMSF values. Negativeformula image values correspond to stabilized regions.
Figure 4
Figure 4
Geometry of active site channel. (A) Two-dimensional histograms showing the distribution of radii along the channel length for the apo, IP4-bound, DAD-bound, and ternary WT simulations, as well as for the apo R265P mutant. (B) The stable channel leading to the active site, from simulations of the HDAC3:IP4:DAD complex is shown schematically, with average diameters indicated along the channel length.
Figure 5
Figure 5
Population analysis of Tyr298formula image dihedral angle. (A) Normalized probability of theformula image side chain dihedral angle shows two states (inward and outward) sampled in the HDAC3 simulations. (B) Cartoon representation of HDAC3 from the HDAC3:IP4:DAD (black) and apo (green) simulations are superimposed to highlight the two Tyr298 conformations. An arbitrary acetyllysine peptide substrate was docked into the active site to show the functional relevance of the inward Tyr298 conformation (hydrogen atoms are not shown).

References

    1. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38–51. - PubMed
    1. de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737–749. - PMC - PubMed
    1. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277:8–21. - PubMed
    1. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. In: Yao TP, Seto E, editors. Histone deacetylases: the biology and clinical implication. Spinger-Verlag Berlin: Heidelberg; 2011. pp. 13–37.
    1. Gottesfeld JM, Pandolfo M. Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol. 2009;4:775–784. - PMC - PubMed

LinkOut - more resources